Cargando…

Cyclin C: A new responser for chemosensitivity in cancer

The resistance to cisplatin‐based chemotherapy is a common cause of poor prognosis in cancer patients. Cisplatin stimulation causes cyclin C translocating to mitochondria, and in turn induces mitochondrial fission. However, little is known about the role of cyclin C in mitochondrial dysfunction in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shuai, Jin, Xiaofeng, Zhou, Chengwei, Gong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042672/
https://www.ncbi.nlm.nih.gov/pubmed/35475325
http://dx.doi.org/10.1002/ctm2.833
_version_ 1784694711173251072
author Fang, Shuai
Jin, Xiaofeng
Zhou, Chengwei
Gong, Zhaohui
author_facet Fang, Shuai
Jin, Xiaofeng
Zhou, Chengwei
Gong, Zhaohui
author_sort Fang, Shuai
collection PubMed
description The resistance to cisplatin‐based chemotherapy is a common cause of poor prognosis in cancer patients. Cisplatin stimulation causes cyclin C translocating to mitochondria, and in turn induces mitochondrial fission. However, little is known about the role of cyclin C in mitochondrial dysfunction in cancer cells challenged with cisplatin. In the present commentary, we bring to the attention of readers the recent report by Jiang et al which revealed the importance of ubiquitylation and translocation of cyclin C in gastric cancer cells in response to cisplatin stimulation for mitochondrial stability. This finding provides new insights into exploring the novel mechanisms of chemoresistance and developing the new chemotherapy synergistic agents in the era of precision oncology.
format Online
Article
Text
id pubmed-9042672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90426722022-04-28 Cyclin C: A new responser for chemosensitivity in cancer Fang, Shuai Jin, Xiaofeng Zhou, Chengwei Gong, Zhaohui Clin Transl Med Commentary The resistance to cisplatin‐based chemotherapy is a common cause of poor prognosis in cancer patients. Cisplatin stimulation causes cyclin C translocating to mitochondria, and in turn induces mitochondrial fission. However, little is known about the role of cyclin C in mitochondrial dysfunction in cancer cells challenged with cisplatin. In the present commentary, we bring to the attention of readers the recent report by Jiang et al which revealed the importance of ubiquitylation and translocation of cyclin C in gastric cancer cells in response to cisplatin stimulation for mitochondrial stability. This finding provides new insights into exploring the novel mechanisms of chemoresistance and developing the new chemotherapy synergistic agents in the era of precision oncology. John Wiley and Sons Inc. 2022-04-26 /pmc/articles/PMC9042672/ /pubmed/35475325 http://dx.doi.org/10.1002/ctm2.833 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Fang, Shuai
Jin, Xiaofeng
Zhou, Chengwei
Gong, Zhaohui
Cyclin C: A new responser for chemosensitivity in cancer
title Cyclin C: A new responser for chemosensitivity in cancer
title_full Cyclin C: A new responser for chemosensitivity in cancer
title_fullStr Cyclin C: A new responser for chemosensitivity in cancer
title_full_unstemmed Cyclin C: A new responser for chemosensitivity in cancer
title_short Cyclin C: A new responser for chemosensitivity in cancer
title_sort cyclin c: a new responser for chemosensitivity in cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042672/
https://www.ncbi.nlm.nih.gov/pubmed/35475325
http://dx.doi.org/10.1002/ctm2.833
work_keys_str_mv AT fangshuai cyclincanewresponserforchemosensitivityincancer
AT jinxiaofeng cyclincanewresponserforchemosensitivityincancer
AT zhouchengwei cyclincanewresponserforchemosensitivityincancer
AT gongzhaohui cyclincanewresponserforchemosensitivityincancer